Please login to the form below

Not currently logged in


This page shows the latest rFIXFc news and features for those working in and with pharma, biotech and healthcare.

FDA starts review of Biogen Idec's haemophilia A therapy

FDA starts review of Biogen Idec's haemophilia A therapy

Eloctate was developed in partnership with Swedish Orphan Biovitrum (Sobi), which also collaborated on the development of Biogen Idec's haemophilia B candidate Alprolix (recombinant factor IX Fc fusion protein; rFIXFc).

Latest news

  • Biogen submits haemophilia drug for US approval Biogen submits haemophilia drug for US approval

    Backing the submission of rFIXFc are results from B-LONG, which Biogen says is the largest phase III clinical study in haemophilia B to date. ... This study demonstrated that rFIXFc was both clinically effective and safe, helping to prevent bleeding

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....